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ABSTRACT: Chemical proteomics approaches are widely used to identify molecular targets of existing or novel drugs. This 
manuscript describes the development of a straightforward approach to conjugate azide-labelled drugs via click chemistry 
to alkyne-tagged cell-penetrating fluorescent nanoparticles as a novel tool to study target engagement and/or identification 
inside living cells. A modification of the Baeyer test for alkynes allows monitoring the Cu(I)-catalyzed azide-alkyne cycload-
dition (CuAAC) reaction, guaranteeing the presence of the drug on the solid support. As a proof of concept, the conjugation 
of the promiscuous kinase inhibitor dasatinib to Cy5-labelled nanoparticles is presented. Dasatinib-decorated fluorescent 
nanoparticles efficiently inhibited its protein target SRC in vitro, entered cancer cells and colocalized with SRC in cellulo. 
INTRODUCTION 
Drug discovery efforts across industry and academia has 
generated extensive libraries of small molecule com-
pounds that are recurrently used in high-throughput 
screening campaigns. One of such tests employs cell assays 
to search for compounds that elicit phenotypic responses 
in particular disease models in a target agnostic manner. 
This approach, so-called phenotypic screening, is aimed to 
accelerate the earlier stages of drug discovery and, poten-
tially, favor the finding of first-in-class inhibitors1–3. After a 
phenotypic hit or lead is found, one of the main challenges 
is to elucidate the mechanism of action responsible for the 
observed pharmacological effect,4 as the assays only pro-
vide information on compounds’ activity in the cell model 
of choice without informing on the target.5 Consequently, 
target identification (ID) studies are often performed to 
support subsequent lead optimization campaigns.  
Among the strategies developed for target ID, chemical 
proteomics enable to interrogate the full proteome for 
direct drug-target interactions. Most chemical proteomics 
approaches combine affinity chromatography with ad-
vanced mass spectrometry to enrich and facilitate target 
identification from complex biological samples6. An alter-
native approach has been proposed to directly visualize 
drug-target interactions in cells using drug-labelled 
nanodevices and fluorescent immunocytochemistry7. Re-
gardless of the method, an essential step in these strategies 
is the conjugation of the drug to the solid support, which 
typically requires individual optimization of the coupling 
process for each drug8. Therefore, the development of 
versatile, robust conjugation methods are essential to 
facilitate the performance of target ID studies both in cell 
lysates and in native biological environments.  
Herein, we present a straightforward procedure for the 
conjugation of azide-tagged drugs to miniaturized solid 
supports by click chemistry, along with an analytical 
method to rapidly determine whether the coupling reac-
tion has been successful. As a proof of concept of the strat-
egy, the synthesis, characterization and biological valida-
tion ― in vitro and in cellulo ― of a novel cell-penetrating 
fluorescent nanodevice decorated with the tyrosine kinase 
inhibitor (TKI) dasatinib is reported. 
RESULTS AND DISCUSSION 
Selection and Development of Azide-Tagged Dasatinib. 
Dasatinib is a potent promiscuous kinase inhibitor ap-
proved by the FDA for the treatment of chronic myeloid 
leukaemia (CML) after acquired resistance to imatinib9. 
Dasatinib’s therapeutic effect is mediated by inhibition of 
the constitutively-active fusion protein BCR-ABL, which is 
the product of an aberrant chromosomal translocation and 
responsible for CML oncogenesis. Nevertheless, dasatinib 
also inhibits a wide range of kinases including the nonre-
ceptor tyrosine kinase SRC and its family members (LCK, 
HCK, YES, FYN, FGR, BLK, LYN, FRK), receptor tyrosine 
kinases (KIT, PDGFR, DDR1/2, c-FMS, ephrin receptors), 
and TEC family kinases (TEC and BTK)10, representing a 
good example of a promiscuous drug with potential use 
against numerous clinical disorders. The high potency of 
dasatinib, its interesting polypharmacological properties 
and its easy-to-functionalize chemical structure made it an 
optimal candidate to develop and test our strategy.  
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 Scheme 1. Synthesis of dasatinib-decorated fluorescently-labelled cell-penetrating nanoparticles. 
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To introduce an azide “handle” in dasatinib for CuAAC 
reactions while retaining the essential kinase binding ele-
ments of its structure, the terminal hydroxyl group of the 
hydroxyethylpiperazinyl moiety was modified. The role of 
this moiety is to impart water solubility to the compound7 
and it is displayed outside the protein in the SRC-dasatinib 
co-crystal structure11. The substitution of the OH of da-
satinib by N3 was efficiently carried out using a reported 
procedure with minor modifications7,12. Briefly, chlorina-
tion of that position was achieved by treating dasatinib 
with mesyl chloride and trimethylamine. The correspond-
ing chloro derivative dasatinib-Cl (2) was then reacted 
with sodium azide to obtain derivative dasatinib-N3 (3) 
(Scheme 1, see full synthetic details in the Supp. Inf.). Cell 
viability assays against breast cancer MDA-MB-231 cells 
demonstrated that 3 retained the anti-proliferative prop-
erties of the parent drug 1 (see Supp. Inf.).  
Synthesis of dasatinib-decorated Cy5-labelled cell-
penetrating nanospheres. In cellulo chemical proteomics 
has the potential to provide more biologically relevant 
results by studying drug-target interactions in the native 
cellular environment13. It also provides a method to study 
target engagement, a relevant validation step in drug dis-
covery programs. The development of facile and reliable 
strategies to conjugate drugs and fluorescent labels on 
devices with the capacity to penetrate cells without induc-
ing toxicity is very attractive in this field. 500nm cross-
linked polystyrene nanospheres with demonstrated capac-
ity to safely penetrate a wide variety of cell types14–19 were 
redesigned for the goals of this project (Scheme 1). NH2-
NP500 (4) were synthesized and functionalized according 
to previous reports17,20. To increase biocompatibility, pre-
vent unspecific protein binding and maximize the freedom 
of the conjugated drug molecules, 4 were PEGylated before 
and after incorporation of the dye. By sequential coupling 
and orthogonal deprotection steps (Fmoc/Dde deprotec-
tion strategy21), bifuntionalized doubly-PEGylated nano-
particles (NPs) were labeled with the far-red fluorescent 
dye Cy5 (NH2-Cy5-PEG-NP500, 9). Then an alkyne handle 
was incorporated onto the NPs by conjugation of propiolic 
acid22 to generate Alk-Cy5-PEG-NP500 (10). Finally, reac-
tion of 10 and 3 in the presence of CuI and ascorbic acid23 
gave rise to dasatinib-decorated Cy5-tagged nanospheres, 
DAS-Cy5-PEG-NP500 (11) (see synthesis and loadings in 
the Supp. Inf.). Number of NPs per unit of volume was 
calculated by spectrophotometry according to previous 
reports24 (see calculations in the Supp. Inf).  
Analytical determination of dasatinib incorporation 
onto the solid support. Although CuAAC reactions are 
typically described as virtually quantitative even under 
mild conditions25,26, click reactions on solid phase typically 
need optimized conditions to reach these standards27,28. To 
confirm the effective coupling of 3 to the alkyne-tagged 
NPs 10, a series of analytical methods were attempted: (i) 
detection of unreacted alkynes on the solid support by 
modification of the Baeyer test for alkynes; (ii) Zeta poten-
tial characterization of NPs at different steps of the synthe-
sis; (iii) validation by NMR and mass spectrometry of the 
functionalization strategy by solid phase synthesis using 
an amino-functionalized resin (Rink amide resin).  
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Figure 1. (a) Modification of the Baeyer test for alkynes detects the presence of unreacted alkynes on the NP surface. After reac-
tion of each NP type with KMnO₄, supernatants were analyzed for absorbance in a Nanodrop 3000 at 420nm. Data are means of 
fold increase related to KMnO₄ absorbance. Error bar= ± SEM; n=3. (b) Zeta potential distribution of each NP type analyzed by a 
ZetaSizer Nano ZS. 
 
The Baeyer test is routinely used in chemistry labs to de-
tect the presence of double or triple carbon-carbon bonds 
based on the capacity of KMnO4 to oxidize alkenes and 
alkynes. Aqueous reduction of KMnO4 (violet color) pro-
duces MnO2 (blackish / brown color), a change that is de-
tectable by spectrophotometry in the range of 250 to 500 
nm24. Therefore, we anticipated that this method could be 
used to detect unreacted alkynes on the NPs and thereby 
assess the efficacy of the drug incorporation reaction onto 
the solid support. DAS-Cy5-PEG-NP500 (11) were treated 
with an aqueous solution of KMnO4 and absorbance spec-
tra analyzed, with the test of NH2-Cy5-PEG-NP500 (9) and 
Alk-Cy5-PEG-NP500 (10) under the same conditions being 
used as negative and positive controls, respectively (see 
full details in the Suppl. Inf.). After exploring different 
reaction conditions and careful spectroscopic analysis to 
improve the method, the measurement of the changes in 
the absorbance values at 420 nm after 5 min reaction in 
comparison to the unreacted KMnO4 solution was found to 
be optimal. As shown in Figure 1a, analysis of the reaction 
of the positive control Alk-Cy5-PEG-NP500 resulted in a 
significant increment of absorbance at 420 nm, a change 
that was undetectable for NH2-Cy5-PEG-NP500 (which do 
not contain triple bonds). Importantly, the intensity of the 
signal was significantly reduced in DAS-Cy5-PEG-NP500, as 
it would be expected after conjugation with 3 by CuAAC. 
This simple analytical test served to verify that the click 
reaction took place at a relatively high yield, yet some 
unreacted alkynes were still present in the structure of 
DAS-Cy5-PEG-NP500, most probably being those less-
accessible alkynes found in the interior of the polymeric 
framework of the NPs. An estimation of the CuAAC reac-
tion yield can be performed with this spectrophotometric 
method, giving a value of 63.6%. Unreacted alkynes are 
likely to be found in the interior of the NPs, as steric con-
straints may affect the reaction efficacy. 
Chemical moieties displayed at the outer layer of NPs in-
fluence the surface charge and consequently the Zeta po-
tential of these colloidal structures29. To further validate 
the results obtained from the Baeyer test, the conjugation 
of dasatinib to the NPs was also assessed by measuring 
Zeta potential of NH2-Cy5-PEG-NP500, Alk-Cy5-PEG-NP500 
and DAS-Cy5-PEG-NP500. Figure 1b shows a displacement 
of Zeta potential distribution to the negative range when 
amines were substituted by alkynes, whereas upon drug 
conjugation the presence of the drug on the NP displaces 
the Zeta potential to less negative values, providing further 
qualitative evidence of the success of the CuAAC reaction. 
As a final proof, rink amide resins (NH2-RINK, typically 
used in solid phase peptide synthesis) were treated with 3 
using the same reaction conditions used for the functional-
ization of the NPs (see Scheme 1). Following release of the 
corresponding triazolo-modified dasatinib derivate from 
the solid support by linker cleavage in acidic conditions, 
NMR analysis confirmed the efficacy of this conjugation 
reaction (see Supp. Inf.).  
Biological assays. To assess if the biological activity of the 
drug is maintained after conjugation onto the NPs, DAS-
Cy5-PEG-NP500 were incubated with recombinant SRC and 
the activity of the kinase analyzed using a luminescence 
commercial kit. NPs without dasatinib (NH2-Cy5-PEG-
NP500) were used as negative control. As shown in Figure 
2a, a concentration dependent reduction in SRC activity 
was observed in the presence of DAS-Cy5-PEG-NP500, with 
a 50% of inhibition observed at 2,041 x 106 NPs (51 x 103 
NP / μL). By calculating the amount of drug per NP, the IC50 
value was estimated to be 33.4 nM.  
Crosslinked polystyrene NPs have been previously shown 
to rapidly enter a wide range of cell types14-19,30. To prove 
that the presence of dasatinib does not interfere with the 
internalization process, cell uptake into MDA-MB-231 cells 
was analyzed by flow cytometry (Figure 2b and Supp. Inf.) 
and time-lapse imaging (Movie S1). Cells exhibiting fluo-
rescence in the Cy5 channel were considered as “nanofect-
ed” and multiplicity of nanofection 50 (MNF50) values 
were calculated as the ratio of nanoparticles per cell nec-
essary to “nanofect” 50% of the cell population24. As shown 
in Figure 2b, MNF50 values of DAS-Cy5-PEG-NP500 only 
were slightly inferior when compared to the unclicked 
control NH2-Cy5-PEG-NP500, although no differences in 
internalization efficiency were observed at ≥300 NPs/cell.   
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Figure 2. (a) Dasatinib-decorated NPs inhibit SRC kinase activity in a dose-dependent manner as measured by ADP Glo lumines-
cent kinase assay. (b) Study of cellular uptake. MDA-MB-231 cells were incubated with concentrations ranging from 3 to 3000 
DAS-Cy5-PEG-NP500 or NH2-Cy5-PEG-NP500 per cell for 18 h and analyzed by flow cytometry. Dasatinib-decorated nanoparticles 
by MDA-MB-231 cells shows equivalent efficiency than for the control NPs at ≥300 NPs/cell. (c) Representative example of DAS-
Cy5-PEG-NP500 internalized by MDA-MB-231 cells, Z-stack section imaged by confocal microscopy and zoomed. MDA-MB-231 cells 
were incubated with 3000 NH2-Cy5-PEG-NP500 or DAS-Cy5-PEG-NP500 per cell (magenta) for 24 h, processed for immunocyto-
chemistry and stained with anti-SRC primary and Dylight 405 secondary antibodies (cyan to white). (d) DAS-Cy5-PEG-NP500 colo-
calize with SRC kinase. Mask image of (c) facilitates visualization of colocalization pixels (in white). (e) Pearson’s correlation coeffi-
cient was obtained with ZEN black software from images at zoom factor 1x and subjected to unpaired t-test with GraphPad Prism. 
Data are mean ± SEM of duplicates of four independent experiments, ***P < 0.001. 
Target engagement study. To test the functionality of the 
nanodevices in cells, we next performed a target engage-
ment assay. Triple negative breast cancer MDA-MB-231 
cells were selected to this study as SRC protein is highly 
overexpressed in these cells31. MDA-MB-231 cells were 
treated with DAS-Cy5-PEG-NP500 for 24 h and target-NP 
localization studied by confocal microscopy. The presence 
of a Cy5 fluorescent moiety on the NPs along with their 
size (500 nm) enabled the visualization of NPs by confocal 
microscopy into living cells. Immunocytochemistry analy-
sis was carried out to visualize the SRC protein in the cells 
using an anti-SRC primary antibody and a fluorescent sec-
ondary antibody (Dylight 405). Z-stack images were ac-
quired to image the NPs distributed throughout the cyto-
plasm (Figure 2c,d). Upon immunocytochemistry, image 
analysis showed co-localization of DAS-Cy5-PEG-NP500 
with SRC protein in MDA-MB-231 cells. In contrast, the 
control NPs not decorated with dasatinib (NH2-Cy5-PEG-
NP500) showed no colocalization with the target (see Supp. 
Inf.). These results were further confirmed by calculation 
of the Pearson’s correlation coefficient (Figure 2e), 
demonstrating linear correlation (positive value) between 
the localization of DAS-Cy5-PEG-NP500 and SRC. In con-
trast, a negative value was obtained by analysis the locali-
zation of NH2-Cy5-PEG-NP500 and SRC. These results prove 
the capacity of DAS-Cy5-PEG-NP500 to efficiently engage 
with a specific target in cellulo.  
CONCLUSIONS 
In conclusion, herein we have presented a novel drug-
decorated nanoprobe with the capacity to penetrate 
mammalian cells and bind target proteins in the intracellu-
lar environment. The use of a conjugation strategy based 
on the efficient CuAAC reaction makes this approach ac-
cessible to many different drugs by simple incorporation of 
an azide handle. Caution, however, should be taken when 
assuming a quantitative yield for click reactions on minia-
turized devices. To avoid false negatives, a rapid spectro-
photometric test for click reactions on alkyne-tagged solid 
supports was developed based on the Baeyer test. This 
method can be used to estimate the yield of coupling reac-
tion by detecting unreacted alkynes on the solid support. 
As a proof of concept, fluorescent NPs were functionalized 
with dasatinib and the incorporation of the drug confirmed 
by different analytical methods. Dasatinib-decorated NPs 
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 induced a reduction in SRC activity in vitro, further demon-
strating drug incorporation on the solid support, but also 
proving a correct spatial arrangement of the conjugate that 
maintained drug bioactivity. These NPs were efficiently 
internalized into living MDA-MB-231 cells and, further-
more, demonstrated binding to the target protein (SRC 
kinase) in cellulo, proving the capacity of this novel 
nanodevice to detect drug-target interactions in complex 
living environments. The size of the nanoprobe (~500 nm 
in ⌀) was selected based on the technical limitations of 
conventional fluorescence microscopy.32 Nevertheless, if 
high-resolution imaging techniques are available, the ver-
satile methodology presented herein could be readily im-
plemented on NPs of smaller size.33  
MATERIALS AND METHODS 
General chemistry protocols. All commercially available 
chemicals were obtained from either Fisher Scientific, 
Matrix Scientific, Sigma-Aldrich or VWR International Ltd. 
Reactions were performed under inert atmosphere (nitro-
gen) using anhydrous solvents. NMR spectra were record-
ed at ambient temperature on a 500 MHz Bruker Avance 
III spectrometer. Samples were dissolved in deuterated 
solvents commercially available from Sigma-Aldrich. 1H 
NMR spectra: chemical shifts are reported in parts per 
million (ppm) relative to tetramethylsilane. The data is 
presented as follows: chemical shift, integration, multiplici-
ty (s = singlet, d = doublet, t = triplet, q = quartet, m = mul-
tiplet), coupling constants as a J value in Hertz (Hz) and 
interpretation. The number of protons (n) for a given res-
onance is indicated as nH, and is based on spectral integra-
tion values. The data is presented as follows: chemical shift 
and assignment. TLCs were ran on Merck TLC Silica gel 60 
F254 plates, typically 5 cm x 10 cm, and monitored using a 
254 nm UV source. High resolution mass spectra were 
recorded by the MS Department of the University of Edin-
burgh on a Thermo MAT 900 XLP high resolution, double 
focussing mass spectrometer. All the couplings were car-
ried out on the Eppendorf Thermomixer® comfort and 
washed after centrifugation in an Eppendorf mini centri-
fuge.  
Conjugation of dasatinib to NPs. 8 (1 mL; 1 eq) were 
suspended in DMF (1 mL). Separately, propiolic acid (50 
eq) was dissolved in DMF and activated by the addition of 
oxyma (50 eq) for 4 minutes at r.t. before the addition of 
DIC (50 eq; Sigma-Aldrich) and mixed for 8-10 minutes at 
r.t. The solution mixture was then added to nanospheres 
and suspension mixed on the Thermomixer at 1400 rpm 
for 14 hours at 25°C to obtain akyne-functionalized nano-
spheres 10 after centrifugation and subsequently washing 
with DMF (3 x 1 mL) MeOH (3 x 1 mL), deionized water (3 
x 1 mL). 500μL of 10 were washed, suspended in DMF and 
centrifuged. Separately, a mixture of DMF: piperidine (4:1) 
was degassed and a solution of CuI (30 eq), ascorbic acid 
(60 eq), 3 (30 eq) in 500μL degassed DMF: piperidine (4:1) 
under nitrogen bubbling. This mixture was added onto 
resins while bubbling nitrogen, sealed and mixed over-
night in a rotary wheel. Dasatinib-labelled nanospheres, 11 
were obtained by centrifugation and subsequently washed 
with DMF (3 x 500μL), MeOH (3 x 500μL), deionized water 
(3 x 500μL). 
Baeyer test for alkynes. 1 μL of stock KMnO4 solution (2.5 
mM) was added to 5 x 108 NPs or 0.5 mg rink amide resins 
to a final volume of 10 μL in water. NPs and resins were 
then centrifuged at 13000 g for 5 minutes in an Eppendorf 
centrifuge and absorbance spectra were analyzed. 420 nm 
absorbance was represented as fold increase to control 
solution of KMnO4. 
Dynamic Light Scattering and Zeta potential. The hy-
drodynamic size and Zeta potential of intermediate and 
final nanoparticle configurations were measured on a 
Malvern Zetasizer Nano-ZS (Malvern, Malvern Hills, UK) in 
molecular biology grade water in a disposable sizing cu-
vette for size measurements or clear disposable zeta cu-
vette for zeta potential measurements. 
Kinase activity assay. Recombinant full-length human 
SRC activity was detected by luminescence using ADP-
Glo™ Kinase Assay + SRC Kinase Enzyme System 
(Promega), according to manufacturer instructions in half-
area solid white 96-well plates at a total volume of 40μL. 
The influence of a range of serial dilutions from 25 x 106 
NPs, control NPs or free drug on SRC activity (0.154 ng / 
μL) were analyzed by luminescence using a GloMax® Multi 
(Promega) with an integration time of 0.5s and normalized 
to internal controls. 
Cell culture. MDA-MB-231 cells were cultured in DMEM 
(Gibco), supplemented with 10% (vol / vol) FBS (Gibco), 
2mM L-Glutamine (Gibco) in a standard incubator (95% 
humidity, 5 % CO2) and subcultured twice per week. Se-
rum-free medium was used for 6 h during incubations with 
NPs to prevent nanoparticle aggregation. 
Uptake efficiency. For flow cytometry assays, 5 × 105 
MDA-MB-231 cells were seeded in 24-well plates and sta-
bilized in an incubator for 18 h. Subsequently 3,000, 1,000, 
300, 100, 30, 10, 3 or 0 of 9 / cell or 11 / cell were incu-
bated in 500 μL of serum-free DMEM to evaluate cellular 
uptake. After 6 h, an equal volume of DMEM containing 2X 
FBS was added to all wells and cells were allowed to stabi-
lize overnight. After washing with PBS, living cells were 
trypsinized for 5 min, washed twice with PBS, and collect-
ed in 96 well plates with round bottom. Cells were ana-
lyzed by flow cytometry with a BD Fortessa X-20 (Becton 
Dickinson & Co., NJ, USA) equipped with 4 lasers: Blue 
Laser (488 nm) FSC, Red Laser (640 nm), Violet Laser (405 
nm) and a Yellow Green Laser (561 nm) with automated 
plate loader system BD HTS. The Cy5 emission fluores-
cence was detected in the APC channel (640-670 / 30 nm). 
The data were analyzed using BD FACSDiva software ver-
sion 8.0.1 for data acquisition and FlowJo® (Flowjo, LLC, 
OR, USA) for data analysis. Gate thresholds were adjusted 
to non-nanofected cells and 5 nanofected cells and main-
tained throughout the experiments. Percentages of cells 
containing 9 or 11 were represented versus log (ratios 
NP/cell) and adjusted to a sigmoidal dose-response curve 
using GraphPad Prism Software. MNF50 values were calcu-
lated as the ratio NP / cell necessary to obtain a 50 % of 
cells containing nanoparticles. 
Confocal microscopy colocalization. MDA-MB-231 cells 
were seeded on 10 mm poly-L-Lysine pre-coated co-
verslips in 24 well plates (10000 cells/well). In parallel, 6 x 
107 of 9, 11, 5 or NP-free controls were incubated in 10 μL 
5 % BSA / H2O overnight at 4 ºC to block unspecific bind-
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 ing34 (Supp. Info.). Nanoparticles were thoroughly dis-
persed in a sonication bath for 15 min. Cells were then 
incubated in the presence or in the absence of 3000 NPs in 
500 μL of serum-free DMEM in duplicates. After 6 h, 500 
μL of DMEM supplemented with 2x FBS were added to 
each of the wells and cells were kept in an incubator for 
other 18 h. NPs and cells were then fixed with paraformal-
dehyde (4 % v/v) for 10 min and washed 3 times with PBS 
every 5 min. Cells were permeabilized for 15 min with 0.3 
% Tween / PBS and washed 3 times with PBS every 5 min. 
Coverslips were incubated in blocking buffer (0.3 % BSA, 
10 % FBS, 5 % non-fat dry milk, 0.1 % Tween in PBS) for 
30 min. Anti-Src Rabbit mAb (Cell Signaling Technology) 
was incubated in milk-free blocking buffer (0.3 % BSA, 10 
% FBS, 0.1 % Tween in PBS) for 2 h at a dilution of 1:400. 
After washing 3 times in 0.1 % Tween / PBS, coverslips 
were incubated for 30 min with Goat anti-Rabbit IgG (H+L) 
secondary antibody, DyLight 405 conjugate (Thermofisher 
Scientific) in milk-free blocking buffer (0.3 % BSA, 10 % 
FBS, 0.1 % Tween in PBS) at a dilution of 1 : 400. Co-
verslips were washed twice with 0.1 % Tween / PBS, and 
mounted with Mowiol® (Sigma-Aldrich) on a slide. NPs 
and SRC localization was imaged using a scanning confocal 
inverted microscope LSM 710 Axio Observer (Carl Zeiss, 
Jena, Germany). The images were acquired with a Plan-
Apochromat 63x / 1.4 OIL DIC M27 immersion objective 
and software ZEN 2010 (Carl Zeiss, Jena, Germany). Confo-
cal images of 9, 11, 5 or NP-free controls in cell lysates and 
cells were obtained in a sequential mode using the follow-
ing settings: 1) a 405-nm diode excitation laser (30 mW) at 
2 % power, an emission of in a range of 410 nm to 488 nm 
with a main beam splitter MBS-405, and a pinhole of 1.0 
Airy Unit (0.6 µm optical section); and 2) a 633 nm HeNe 
excitation laser (5.0 mW) at 15 % power, an emission 
wavelength range of 636-742 nm with a MBS-
488/543/633, and a pinhole of 1.0 Airy Unit (0.7 µm opti-
cal section). Transmitted images were obtained with a T 
PMT. Z-stack images were recorded in an average range of 
6 μm, 13 slices and a constant interval of 0.5 μm, according 
to NP size, to localize 500 nm nanoparticles throughout the 
cell volume. Images were processed with Software ZEN 
2010 Black Edition (Carl Zeiss, Jena, Germany) to obtain 
overlap coefficient and Pearson’s Correlation Coefficient as 
co-localization coefficients. Both coefficients, crosshair 
diagrams and mask images were obtained after calibration 
according to negative controls and maintained for all the 
experiments (Supp. Inf.). Unpaired t-test statistical analysis 
of four independent experiments was performed using 
Graph Pad Prism 5.0 for Windows GraphPad Software, La 
Jolla California USA, www.graphpad.com. 
ASSOCIATED CONTENT  
Full synthetic details, characterization spectra, results of con-
trol nanoparticles and resins, complementary biological data, 
confocal microscopy images. This material is available free of 
charge via the Internet at http://pubs.acs.org. 
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